Table 3:
Associations between stain use and risk of ovarian cancer, stratified by histologic subtype, age at first use and duration of use.
| Statin use |
Age at first use (years) |
Duration of statin use (years) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | No N (%) |
Yes N (%) |
Adjusted* OR (95% CI) |
Adjusted* OR (95% CI) |
Adjusted* OR (95% CI) |
Adjusted* OR (95% CI) |
Adjusted* OR (95% CI) |
||||
| <60 | ≥60 | <5 | ≥5 | ||||||||
| Controls | 1855 (88) | 245 (12) | 1.00 (referent) | 136 (56) | 1.00 (referent) | 107 (44) | 1.00 (referent) | 148 (61) | 1.00 (referent) | 95 (39) | 1.00 (referent) |
| Ovarian cancer | |||||||||||
| By histologic type, grade, and invasiveness | |||||||||||
| All invasive | 1445 (90) | 169 (10) | 0.65 (0.52 - 0.82) | 96 (57) | 0.72 (0.54 - 0.97) | 73 (43) | 0.57 (0.41 - 0.80) | 98 (58) | 0.66 (0.50 - 0.88) | 71 (42) | 0.64 (0.45 - 0.90) |
| Serous all invasive | 850 (88) | 117 (12) | 0.69 (0.53 - 0.90) | 61 (52) | 0.76 (0.55 - 1.07) | 56 (48) | 0.63 (0.44 - 0.91) | 68 (58) | 0.72 (0.52 - 0.99) | 49 (42) | 0.67 (0.45 - 0.97) |
| Serous low grade | 46 (94) | 3 (6) | 0.41 (0.12 - 1.41) | 1 (33) | 0.25 (0.03 - 1.91) | 2 (67) | 0.67 (0.15 - 3.01) | 2 (67) | 0.44 (0.10 - 1.91) | 1 (33) | 0.37 (0.05 - 2.84) |
| Serous high grade | 804 (88) | 114 (12) | 0.70 (0.54 - 0.92) | 60 (53) | 0.79 (0.57 - 1.11) | 54 (47) | 0.62 (0.43 - 0.90) | 66 (58) | 0.73 (0.53 - 1.01) | 48 (42) | 0.68 (0.46 – 1.00) |
| All non-serous invasive | 595 (92) | 52 (8) | 0.56 (0.40 - 0.79) | 35 (67) | 0.68 (0.45 - 1.03) | 17 (33) | 0.41 (0.23 - 0.71) | 30 (58) | 0.55 (0.35 - 0.85) | 22 (42) | 0.58 (0.35 - 0.96) |
| Endometrioid invasive | 297 (91) | 30 (9) | 0.70 (0.45 - 1.09) | 19 (63) | 0.78 (0.45 - 1.33) | 11 (37) | 0.61 (0.31 - 1.22) | 18 (60) | 0.72 (0.42 - 1.25) | 12 (40) | 0.69 (0.35 - 1.35) |
| Clear cell invasive | 104 (91) | 10 (9) | 0.67 (0.32 - 1.38) | 8 (80) | 1.01 (0.46 - 2.25) | 2 (20) | 0.27 (0.06 - 1.16) | 6 (60) | 0.70 (0.29 - 1.73) | 4 (40) | 0.61 (0.21 - 1.80) |
| Mucinous† | 234 (97) | 8 (3) | 0.39 (0.18 - 0.82) | 4 (50) | 0.32 (0.11 - 0.89) | 4 (50) | 0.51 (0.18 - 1.46) | 4 (50) | 0.30 (0.11 - 0.85) | 4 (50) | 0.56 (0.20 - 1.60) |
| All borderline | 407 (96) | 19 (4) | 0.70 (0.42 - 1.17) | 14 (74) | 0.83 (0.46 - 1.49) | 5 (26) | 0.50 (0.20 - 1.29) | 7 (37) | 0.40 (0.18 - 0.88) | 12 (63) | 1.30 (0.68 - 2.50) |
| Serous borderline | 236 (94) | 14 (6) | 0.94 (0.51 - 1.72) | 12 (86) | 1.27 (0.66 - 2.43) | 2 (14) | 0.40 (0.09 - 1.68) | 5 (36) | 0.53 (0.21 - 1.34) | 9 (64) | 1.84 (0.86 - 3.90) |
| All non-serous borderline | 171 (97) | 5 (3) | 0.40 (0.16 - 1.03) | 2 (40) | 0.26 (0.06 - 1.10) | 3 (60) | 0.63 (0.19 - 2.10) | 2 (40) | 0.25 (0.06 - 1.04) | 3 (60) | 0.70 (0.21 - 2.34) |
| Stage | |||||||||||
| I - II | 991 (93) | 74 (7) | 0.63 (0.47 - 0.85) | 48 (65) | 0.72 (0.50 - 1.03) | 26 (35) | 0.52 (0.32 - 0.83) | 41 (55) | 0.57 (0.39 - 0.84) | 33 (45) | 0.73 (0.47 - 1.13) |
| III - IV | 854 (88) | 113 (12) | 0.69 (0.53 - 0.90) | 61 (54) | 0.76 (0.54 - 1.06) | 52 (46) | 0.63 (0.44 - 0.92) | 64 (57) | 0.69 (0.50 - 0.95) | 49 (43) | 0.71 (0.49 - 1.04) |
*
Adjusted for age (continuous), study site (Massachusetts, New Hampshire), study phase (1, 2, 3), BMI (continuous), parity (continuous), educational status (≤12 grade, >12 grade), oral contraceptive use (yes/no), tubal ligation (yes/no), family history of ovarian cancer (yes/no), smoking status (never, former, current smoker), menopausal status and HRT use (premenopausal, postmenopausal no HRT use, postmenopausal and used HRT).
†
Includes borderline and invasive cases. The OR (95% CI) for statin use in borderline and invasive mucinous invasive cases is 0.32 (0.10-1.06) and 0.42 (0.16-1.11), respectively.